Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Jan;225(1):35-44.
doi: 10.1016/j.rceng.2024.10.007. Epub 2024 Oct 28.

2024 Spanish Society of Internal Medicine (SEMI) recommendations for the management of cancer-associated venous thromboembolism

Affiliations
Practice Guideline

2024 Spanish Society of Internal Medicine (SEMI) recommendations for the management of cancer-associated venous thromboembolism

A Villalobos et al. Rev Clin Esp (Barc). 2025 Jan.

Abstract

Vennous thromboembolism (VTE) is a common complication associated to greater mortality in patients with cancer. Its etiology is multifactorial and depends on the characteristics and co-morbidities of the patient, the tumor type and extension, and the oncological treatment. The management of VTE is more complex in patients with cancer due to an increased risk of recurrence and major bleeding complications during anticoagulation compared to the general non-oncological population. The above differences have led to the development of specific clinical trials to assess the efficacy and safety of anticoagulant therapy in patients with cancer. The present clinical guidelines are intended to provide general recommendations on the management of cancer-associated VTE according to updated according to the most recent scientific evidence.

Keywords: Cancer-associated thrombosis; Consensus recommendations for clinical practice; Paraneoplastic thrombosis; Recomendaciones de consenso para la práctica clínica; Trombosis asociada al cáncer; Trombosis paraneoplásica.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Aurora Villalobos has received speaker’s fees from the following pharmaceutical companies: Leo Pharma, Pfizer, ROVI, Sanofi, and Techdow and has participated in an advisory role for Pfizer. Pablo Demelo-Rodríguez has received speaker’s fees from the following pharmaceutical companies: Bayer, Bristol-Myers, Daiichi Sankyo, Leo Pharma, Menarini, Pfizer, ROVI, Sanofi, and Techdow and has participated in an advisory role for Leo Pharma, Pfizer, and Techdow. Carme Font has received speaker’s fees from the following pharmaceutical companies: Daiichi Sankyo, Leo Pharma, Pfizer, ROVI, Sanofi, and Techdow and has participated in an advisory role for Leo Pharma and Pfizer.

Publication types

MeSH terms

LinkOut - more resources